Wordt geladen...
The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
The discovery of the incretin hormone glucagon like peptide-1 (GLP-1), and its usefulness in the treatment of type 2 diabetes mellitus (T2DM) followed by the finding that dipeptidyl peptidase-4 (DPP-4) inhibition prevents GLP-1 inactivation, led to the discovery of DPP-728. In 1999, studies with DPP...
Bewaard in:
| Gepubliceerd in: | Eur Endocrinol |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Touch Medical Media
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5813465/ https://ncbi.nlm.nih.gov/pubmed/29632608 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2017.13.02.56 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|